Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old (any gender)
• People who have been diagnosed through pathology testing with locally advanced or metastatic non-small cell lung cancer (a type of lung cancer that has spread or cannot be surgically removed)
• People whose genetic testing has confirmed a specific type of EGFR mutation (a change in a gene linked to lung cancer)
• People who can provide a blood sample taken during or after their cancer worsened while on their most recent EGFR-targeted treatment
• People with a life expectancy of at least 3 months
• People who have at least one measurable tumour that meets specific imaging criteria (previously treated with radiotherapy only counts if clear new growth is shown on imaging)
• People with a physical performance score of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor restrictions on physical activity
• People whose major organs (such as liver, kidneys, and heart) are functioning adequately
• People who are capable of having children and agree to use reliable contraception during the trial
• People who are willing to give written informed consent before joining the study

Who may not be able to join:

• People who have received chemotherapy, radiotherapy, biological therapy, targeted therapy, hormone therapy, immunotherapy, or other anti-cancer treatments within 4 weeks before starting the study drug
• People who have previously been treated with more than one EGFR-targeted therapy
• People who have taken part in another clinical trial or received an unlisted experimental treatment within 4 weeks before starting the study drug
• People who have had major surgery (not including needle biopsies) or a serious injury within 4 weeks before starting the study drug, or who are expected to need planned surgery during the trial
• People who have taken certain strong medications that affect how the body processes drugs (strong CYP3A4 inhibitors or inducers) within 7 days before starting the study drug (confirm with trial site)
• People with known active brain metastases (cancer that has spread to the brain) or evidence of brain tumour progression
• People who have had another primary cancer diagnosed within the past 2 years
• People who still have side effects from previous cancer treatments that have not resolved to a mild level, with some exceptions such as hair loss or certain stable conditions (confirm with trial site)
• People with skin ulcers, pressure sores, chronic leg ulcers, known active stomach ulcers, or wounds that are not healing
• People with a history of severe allergic reactions, or known allergy to any ingredient in the study drug
• People with a severe active infection requiring intravenous antibiotics or hospitalisation at the time of screening, or an uncontrolled active infection within 4 weeks before starting the study drug
• People with known active or suspected autoimmune diseases, or known active eye diseases such as wet age-related macular degeneration or diabetic eye disease affecting the centre of vision
• People who test positive for HIV or syphilis
• People with interstitial lung disease (a condition causing scarring or inflammation in the lungs)
• People with a history of serious heart or cardiovascular disease
• People who are unable to swallow tablets or capsules, or who have a condition that significantly affects how medication is absorbed through the digestive system
• People who require medical intervention for fluid build-up around the lungs or in the abdomen (unless the fluid has been stable for more than 2 weeks after drainage and no further drainage is needed)
• People with known dependence on alcohol or drugs
• People with mental health conditions or who are unlikely to follow the trial requirements
• Women who are pregnant or breastfeeding
• People the trial investigator considers unsuitable for the trial for other reasons

Important: Always verify eligibility with the trial site directly before applying.